Literature DB >> 25772321

The Modulatory Effects of the Polymorphisms in GLA 5'-Untranslated Region Upon Gene Expression Are Cell-Type Specific.

Susana Ferreira1, Carlos Reguenga, João Paulo Oliveira.   

Abstract

Lysosomal α-galactosidase A (αGal) is the enzyme deficient in Fabry disease (FD). The 5'-untranslated region (5'UTR) of the αGal gene (GLA) shows a remarkable degree of variation with three common single nucleotide polymorphisms at nucleotide positions c.-30G>A, c.-12G>A and c.-10C>T. We have recently identified in young Portuguese stroke patients a fourth polymorphism, at c.-44C>T, co-segregating in cis with the c.-12A allele. In vivo, the c.-30A allele is associated with higher enzyme activity in plasma, whereas c.-10T is associated with moderately decreased enzyme activity in leucocytes. Limited data suggest that c.-44T might be associated with increased plasma αGal activity. We have used a luciferase reporter system to experimentally assess the relative modulatory effects on gene expression of the different GLA 5'UTR polymorphisms, as compared to the wild-type sequence, in four different human cell lines. Group-wise, the relative luciferase expression patterns of the various GLA variant isoforms differed significantly in all four cell lines, as evaluated by non-parametric statistics, and were cell-type specific. Some of the post hoc pairwise statistical comparisons were also significant, but the observed effects of the GLA 5'UTR polymorphisms upon the luciferase transcriptional activity in vitro did not consistently replicate the in vivo observations.These data suggest that the GLA 5'UTR polymorphisms are possible modulators of the αGal expression. Further studies are needed to elucidate the biological and clinical implications of these observations, particularly to clarify the effect of these polymorphisms in individuals carrying GLA variants associated with high residual enzyme activity, with no or mild FD clinical phenotypes.

Entities:  

Year:  2015        PMID: 25772321      PMCID: PMC4484901          DOI: 10.1007/8904_2015_424

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  27 in total

1.  Preferential transformation of human neuronal cells by human adenoviruses and the origin of HEK 293 cells.

Authors:  Gerry Shaw; Silas Morse; Miguel Ararat; Frank L Graham
Journal:  FASEB J       Date:  2002-04-10       Impact factor: 5.191

2.  Fabry disease: polymorphic haplotypes and a novel missense mutation in the GLA gene.

Authors:  L Ferri; C Guido; G la Marca; S Malvagia; C Cavicchi; A Fiumara; R Barone; R Parini; D Antuzzi; C Feliciani; A Zampetti; R Manna; S Giglio; C M Della Valle; X Wu; K J Valenzano; R Benjamin; M A Donati; R Guerrini; M Genuardi; A Morrone
Journal:  Clin Genet       Date:  2011-05-25       Impact factor: 4.438

3.  An atypical variant of Fabry's disease with manifestations confined to the myocardium.

Authors:  W von Scheidt; C M Eng; T F Fitzmaurice; E Erdmann; G Hübner; E G Olsen; H Christomanou; R Kandolf; D F Bishop; R J Desnick
Journal:  N Engl J Med       Date:  1991-02-07       Impact factor: 91.245

4.  Genetic analysis of lysosomal alpha-galactosidase A gene in sporadic Parkinson's disease.

Authors:  Guanghua Wu; Shuchao Pang; Xungang Feng; Aimei Zhang; Jifeng Li; Kejin Gu; Jian Huang; Haixin Dong; Bo Yan
Journal:  Neurosci Lett       Date:  2011-06-12       Impact factor: 3.046

5.  The enzyme defect in Fabry's disease.

Authors:  J A Kint
Journal:  Nature       Date:  1970-09-12       Impact factor: 49.962

6.  Isolation and culture of microvascular endothelial cells.

Authors:  L Richard; P Velasco; M Detmar
Journal:  Methods Mol Med       Date:  1999

7.  Fabry disease: characterization of alpha-galactosidase A double mutations and the D313Y plasma enzyme pseudodeficiency allele.

Authors:  Makiko Yasuda; Junaid Shabbeer; Stacy D Benson; Irene Maire; Roger M Burnett; Robert J Desnick
Journal:  Hum Mutat       Date:  2003-12       Impact factor: 4.878

8.  Sequence variations in the first exon of alpha-galactosidase A.

Authors:  J P Davies; B G Winchester; S Malcolm
Journal:  J Med Genet       Date:  1993-08       Impact factor: 6.318

Review 9.  Fabry disease.

Authors:  Dominique P Germain
Journal:  Orphanet J Rare Dis       Date:  2010-11-22       Impact factor: 4.123

10.  Systematic analysis of bicistronic reporter assay data.

Authors:  Jonathan L Jacobs; Jonathan D Dinman
Journal:  Nucleic Acids Res       Date:  2004-11-23       Impact factor: 16.971

View more
  4 in total

1.  Frequency of Fabry disease in a juvenile idiopathic arthritis cohort.

Authors:  Luciana Paim-Marques; Amanda Virginia Cavalcante; Islane Verçosa; Paula Carneiro; Marcia Souto-Maior; Erlane Marques; Simone Appenzeller
Journal:  Pediatr Rheumatol Online J       Date:  2021-06-12       Impact factor: 3.054

2.  Increased glycolipid storage produced by the inheritance of a complex intronic haplotype in the α-galactosidase A (GLA) gene.

Authors:  Javier Gervas-Arruga; Jorge J Cebolla; Pilar Irun; Javier Perez-Lopez; Luis Plaza; Jose C Roche; Jose L Capablo; Jose C Rodriguez-Rey; Miguel Pocovi; Pilar Giraldo
Journal:  BMC Genet       Date:  2015-09-03       Impact factor: 2.797

3.  Fabry disease in the Spanish population: observational study with detection of 77 patients.

Authors:  Irene Vieitez; Olga Souto-Rodriguez; Lorena Fernandez-Mosquera; Beatriz San Millan; Susana Teijeira; Julian Fernandez-Martin; Felisa Martinez-Sanchez; Luis Jose Aldamiz-Echevarria; Monica Lopez-Rodriguez; Carmen Navarro; Saida Ortolano
Journal:  Orphanet J Rare Dis       Date:  2018-04-10       Impact factor: 4.123

4.  Plasma Globotriaosylsphingosine and α-Galactosidase A Activity as a Combined Screening Biomarker for Fabry Disease in a Large Japanese Cohort.

Authors:  Hiroki Maruyama; Atsumi Taguchi; Mariko Mikame; Atsushi Izawa; Naoki Morito; Kazufumi Izaki; Toshiyuki Seto; Akifumi Onishi; Hitoshi Sugiyama; Norio Sakai; Kenji Yamabe; Yukio Yokoyama; Satoshi Yamashita; Hiroshi Satoh; Shigeru Toyoda; Michihiro Hosojima; Yumi Ito; Ryushi Tazawa; Satoshi Ishii
Journal:  Curr Issues Mol Biol       Date:  2021-06-19       Impact factor: 2.976

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.